Strong Quarter for Cepheid - Analyst Blog
April 21 2011 - 12:35PM
Zacks
Cepheid (CPHD)
reported an adjusted EPS of 2 cents during the first quarter of
fiscal 2011, much better than the loss of 6 cents in the year-ago
period and the Zacks Consensus Estimate of a loss of 1 cent.
Revenues during the quarter
increased 25.4% to $60.2 million, beating the Zacks Consensus
Estimate of $57 million. The upside was driven by a 22% growth in
product sales to $57.6 million attributable to strong sales of
reagents and systems. Based on strong revenue growth, Cepheid was
able to improve its bottom line.
Among the different markets, the
Clinical segment consisting of Clinical Systems (up 20% year over
year to $11.6 million) and Clinical Reagents (up 31% to $38.6
million) contributed about 87.2% to total product sales during the
quarter. Cepheid’s Non-Clinical business dropped 6% year over year
to $7.4 million. Sales from North America and the international
market recorded a year-over-year increase of 14% and 53%,
respectively.
Gross margin on product sales
improved to 56% compared with 45% in the first quarter of 2010.
While product sales improved 22%, cost of products sold declined by
3% leading to an improvement in margin. Operating expenses amounted
to $32.6 million, up 33.8% compared with the year-ago quarter,
driven by higher research and development (39.9% annually to $13.6
million), sales and marketing (27.4% to $11.4 million), and general
and administrative expenses (33.5% to $7.6 million).
During the quarter, Cepheid’s 120
GeneXpert systems were installed. In addition, the company placed
58 GeneXpert systems as part of its High Burden Developing Country
Program (HBDC) Program. Including the HBDC systems, a cumulative
total of 2,038 systems have been placed worldwide as of March 31,
2011. At the end of the reported quarter, cash and cash equivalents
were $80.5 million, up from $79.5 million at the end of December
2010.
Outlook
Cepheid reiterated its outlook for
2011 with revenues in the range of $245 million–$255 million.
Moreover, the company expects bottom-line results within a loss of
1 cent to a profit of 4 cents per share.
Recommendation
With a broad portfolio of tests,
the company is one of the leading players in the healthcare
associated infections (HAI) market. Moreover, Cepheid has an
attractive pipeline, the approval of which should boost revenues
further.
However, we remain concerned about
a tight spending environment in the current recessionary situation,
which is impacting the ability of healthcare providers to purchase
capital equipment. Moreover, the company faces tough competition
from several players.
We maintain our ‘Neutral’
recommendation on Cepheid.
CEPHEID INC (CPHD): Free Stock Analysis Report
Zacks Investment Research
Cepheid (NASDAQ:CPHD)
Historical Stock Chart
From May 2024 to Jun 2024
Cepheid (NASDAQ:CPHD)
Historical Stock Chart
From Jun 2023 to Jun 2024